The first 60 days: Post-transplant lymphoproliferative disorder (PTLD)
After an organ or stem cell transplant, the drugs that stop rejection also stop the immune system from policing Epstein-Barr virus, and infected B cells can grow into a lymphoma. The first move is to ease the immunosuppression; then the antibody rituximab, chemotherapy if needed, and, newest of all, off-the-shelf virus-specific T cells that restore the missing immune control. Below, week by week, is what OnCo's record of Post-transplant lymphoproliferative disorder (PTLD) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: All PTLD, first step.
- Medical oncologistNamed in the standard of care for: All PTLD, first step, CD20-positive PTLD not responding to reduced immunosuppression, After allogeneic HSCT, high risk.
- Clinical oncologist (radiotherapy)Named in the standard of care for: All PTLD, first step.
- Transplant and cell therapy teamNamed in the standard of care for: CD20-positive PTLD not responding to reduced immunosuppression, EBV-positive, relapsed or refractory, After allogeneic HSCT, high risk.
- Palliative and supportive care teamNamed in the standard of care for: CD20-positive PTLD not responding to reduced immunosuppression.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Weekly plasma EBV DNA monitoring with pre-emptive rituximab when load rises; reduction of immunosuppression where possible.
- 2.All PTLD, first stepBSH guideline on PTLD (Br J Haematol 2021); ECIL guidelines for EBV after HSCT
Reduce immunosuppression as far as graft safety allows, with close monitoring for rejection; surgery or radiotherapy for localised disease.
- 3.CD20-positive PTLD not responding to reduced immunosuppressionNCCN category Category 2A, NCCN Guidelines: B-Cell Lymphomas (PTLD); PTLD-1 RSST (JCO 2017)
Rituximab weekly for four doses; patients in complete remission continue rituximab consolidation alone, others proceed to R-CHOP (PTLD-1 risk-stratified sequential treatment).
EBV-specific T cells: tabelecleucel (EMA approval 2022; under FDA review) or institutional virus-specific T-cell programmes; clinical trials.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example EBV status of tumourand plasma EBV DNA load, CD20 expression, Recipient EBV serostatus at transplant, Type and intensity of immunosuppression, LDH, stage, performance status and graft involvement), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Non-destructive PTLD, Polymorphic PTLD, Monomorphic PTLD, B-cell.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
All PTLD, first step
- For my situation (all ptld, first step), which of the standard options do you recommend and why?Guideline options include: Reduce immunosuppression as far as graft safety allows, with close monitoring for rejection; surgery or radiotherapy for localised disease.
CD20-positive PTLD not responding to reduced immunosuppression
- For my situation (cd20-positive ptld not responding to reduced immunosuppression), which of the standard options do you recommend and why?Guideline options include: Rituximab weekly for four doses; patients in complete remission continue rituximab consolidation alone, others proceed to R-CHOP (PTLD-1 risk-stratified sequential treatment).
- Am I a candidate for Rituximab, Cyclophosphamide, Doxorubicin or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
EBV-positive, relapsed or refractory
- For my situation (ebv-positive, relapsed or refractory), which of the standard options do you recommend and why?Guideline options include: EBV-specific T cells: tabelecleucel (EMA approval 2022; under FDA review) or institutional virus-specific T-cell programmes; clinical trials.
After allogeneic HSCT, high risk
- For my situation (after allogeneic hsct, high risk), which of the standard options do you recommend and why?Guideline options include: Weekly plasma EBV DNA monitoring with pre-emptive rituximab when load rises; reduction of immunosuppression where possible.
- Am I a candidate for Rituximab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Allogeneic (off-the-shelf) cell therapy, Rituximab, Glofitamab, Epcoritamab?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Rituximab-refractory and EBV-negative PTLD have poor outcomes; EBV-specific T cells, CAR-T and bispecific antibodies are the routes being tested”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “US access to tabelecleucel awaits FDA resolution of manufacturing findings; academic virus-specific T-cell banks fill the gap”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Post-transplant lymphoproliferative disorder (PTLD): the full pageAfter an organ or stem cell transplant, the drugs that stop rejection also stop the immune system from policing Epstein-Barr virus, and infected B cells can grow into a lymphoma. The first move is to ease the immunosuppression; then the antibody rituximab, chemotherapy if needed, and, newest of all, off-the-shelf virus-specific T cells that restore the missing immune control.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Graft-versus-host disease (GVHD) and graft-versus-leukaemia: After a donor transplant, the donor's immune cells may attack the patient's skin, gut and liver (graft-versus-host disease) while also hunting down leftover leukaemia (graft-versus-leukaemia).
- Plasma EBV DNA: Fragments of Epstein-Barr virus DNA in the blood that measure nasopharyngeal carcinoma: used to screen healthy people in endemic regions, to stage, to decide who needs extra treatment after radiotherapy, and to detect relapse.
- Allogeneic stem cell transplant (allo-SCT): Replacing a patient's blood system with a donor's: chemotherapy wipes out the marrow, donor stem cells rebuild it, and the donor's immune cells hunt down leftover leukaemia.
- Epstein-Barr virus (EBV) in cancer: The common glandular-fever virus, carried lifelong by most adults, which in a minority of people drives nasopharyngeal cancer, some stomach cancers and several lymphomas.
Every term links to the glossary.